# A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG

> **NCT00402506** · PHASE3 · COMPLETED · sponsor: **Medicure** · enrollment: 3000 (estimated)

## Conditions studied

- Coronary Artery Bypass Graft Surgery
- Myocardial Ischemia
- Reperfusion Injury

## Interventions

- **DRUG:** (MC-1) Pyridoxal 5'-phosphate

## Key facts

- **NCT ID:** NCT00402506
- **Lead sponsor:** Medicure
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2007-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00402506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00402506, "A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00402506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*